Stage 4 Pancreatic Cancer Prognosis: Survival Data and Variables

Stage 4 (metastatic) pancreatic adenocarcinoma carries a median overall survival of 6–12 months with modern systemic therapy (FOLFIRINOX or gemcitabine/nab-paclitaxel). Key variables influencing individual outcomes:

• Performance status (ECOG 0–1 vs. ≥2)
• Metastatic burden (liver-only vs. multi-organ)
• Molecular profile (BRCA/PALB2 mutations → PARP inhibitor eligibility; MSI-H/dMMR → immunotherapy)
• Response to first-line therapy
• Access to clinical trials
• Comorbidities, nutritional status, social support

Emerging Improvements

Sequencing therapies, maintenance strategies (olaparib for BRCA), and novel agents (KRAS inhibitors, immunotherapy combinations) are extending survival for subsets. Palliative care integration at diagnosis improves quality of life and may prolong survival.

Discussion Points with Oncology Team

• Molecular testing results and targeted options
• Clinical trial eligibility
• Goals of care, advance directives
• Symptom management (pain, nausea, biliary/enteric obstruction)